OCEANiC: TOGA’s New Trial Open to Recruitment

stages of OCEANiC trial

What is OCEANiC? OCEANiC is a phase II multi-centre clinical trial targeting patients with resected stage II to IIIA EGFR mutant NSCLC. The trial provides access to Osimertinib for all patients with EGFR mutations post-surgery. The aim of OCEANiC is to determine if adjuvant chemotherapy can be omitted in patients with resected stage II-IIIA EGFR […]

Five Things to Consider When Participating in a Clinical Trial

Doctor consulting with a patient for clinical trial

Facing a diagnosis can be a daunting journey, rife with uncertainty and difficult decisions. Among these decisions is the choice of whether to participate in a clinical trial. While the prospect may initially seem overwhelming, it’s essential to recognise the potential benefits and weigh them against the uncertainties. In this guide, we’ll explore five critical […]

Three Reasons You Should Participate in Clinical Trials

Hero Image - Female scientist researching lung cancer

In the realm of medical breakthroughs, cancer clinical trials emerge as beacons of hope, guiding us toward innovative treatments and potential cures. These trials represent the frontlines of cancer research, where groundbreaking therapies are meticulously tested before reaching the hands of people living with lung cancer. So, what exactly do these trials entail? Cancer clinical […]

ASM23 highlights

ASM23 Convenor A/Prof Zarnie Lwin

“Shifting The Dial Forward in Lung Cancer Care: It Takes a village” Highlights of the 2023 Annual Scientific Meeting The TOGA 2023 Annual Scientific Meeting highlighted that it truly takes a village to treat lung cancer as it showcased the latest research in immuno- and targeted therapy, thoracic surgery, respiratory medicine, palliative and supportive care […]

Lung Cancer Screening Program

The hand of a doctor is cradling a scanned image of lungs

The Lung Cancer Screening program Announcement by the Minister for Health and Aged Care On 2 May 2023, the Minister for Health and Aged Care announced $263.8 million over four years for a National Lung Cancer Screening Program (LCSP). TOGA welcomed the news as this program will facilitate detection of lung cancer at an earlier […]

MSAC Recommendation for NGS panel testing

Recommendation for improved genetic testing for Non-Small Cell Lung Cancer Patients Recommendation by the Medical Services Advisory Committee (MSAC) Why is gene testing important for lung cancer patients? Non-small cell lung cancer (NSCLC) accounts for about 80% to 85% of lung cancers. The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, or large undifferentiated […]

ASM 2023 Program

ASM23 Speakers

Submit an Abstract Back to 2023 ASM ASM 2023 Program We are pleased to announce that the following speakers have confirmed their participation in the TOGA ASM 2023. We are delighted that the two international speakers, Professors Karen Kelly and Stephen Swisher, have accepted our invitations and will be joining us in-person at the TOGA […]

ASM22 highlights

ASM22 Convenor Dr Melissa Moore and A/Prof Zarnie Lwin

2022 Annual Scientific Meeting Highlights The Dynamic Face of Lung Cancer was certainly showcased at our 2022 Annual Scientific Meeting, with presentations illustrating the latest research and clinical practice in surgery, diagnostics, radiation therapy, targeted therapy, immunotherapy and prevention of risk factors for thoracic cancers. Held as a ‘hybrid’ event, the event attracted 150 face […]

Run and fundraise

Running for #TeamTOGA What is #TeamTOGA? #TeamTOGA is a group of individuals who walk or run to raise money for lung cancer and mesothelioma research by participating in marathons or walking events and collecting donations and sponsors through their own personal fundraising page created by TOGA. #TeamTOGA is reassembling for the 2023 Sun Herald City2Surf, […]


Abstract Submission Guidelines Back to 2023 ASM Abstract Submissions The TOGA Annual Scientific Meeting (ASM) Local Organising Committee (LOC) welcomes abstracts on any scientific study of merit for submission, particularly those that provide new and original data relevant to the Australian and New Zealand environment.  Abstracts may be submitted on any topic relevant to lung […]